Cargando…

Blood Aluminum Levels in Patients with Hemodialysis and Peritoneal Dialysis

Background. This retrospective observational study attempted to examine the prevalence of abnormal blood aluminum levels in dialysis patients, and to explore the association of pathogenic factors, such as demographic, clinical, laboratory as well as the use of phosphate binding drugs, drugs for seco...

Descripción completa

Detalles Bibliográficos
Autores principales: Chuang, Po-Hsun, Tsai, Kai-Fan, Wang, I-Kuan, Huang, Ya-Ching, Huang, Lan-Mei, Liu, Shou-Hsuan, Weng, Cheng-Hao, Huang, Wen-Hung, Hsu, Ching-Wei, Lee, Wen-Chin, Yen, Tzung-Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997989/
https://www.ncbi.nlm.nih.gov/pubmed/35409569
http://dx.doi.org/10.3390/ijerph19073885
_version_ 1784684835394027520
author Chuang, Po-Hsun
Tsai, Kai-Fan
Wang, I-Kuan
Huang, Ya-Ching
Huang, Lan-Mei
Liu, Shou-Hsuan
Weng, Cheng-Hao
Huang, Wen-Hung
Hsu, Ching-Wei
Lee, Wen-Chin
Yen, Tzung-Hai
author_facet Chuang, Po-Hsun
Tsai, Kai-Fan
Wang, I-Kuan
Huang, Ya-Ching
Huang, Lan-Mei
Liu, Shou-Hsuan
Weng, Cheng-Hao
Huang, Wen-Hung
Hsu, Ching-Wei
Lee, Wen-Chin
Yen, Tzung-Hai
author_sort Chuang, Po-Hsun
collection PubMed
description Background. This retrospective observational study attempted to examine the prevalence of abnormal blood aluminum levels in dialysis patients, and to explore the association of pathogenic factors, such as demographic, clinical, laboratory as well as the use of phosphate binding drugs, drugs for secondary hyperparathyroidism and erythropoiesis-stimulating drugs with the blood aluminum levels. Methods. The study included 1175 patients (874 hemodialysis and 301 peritoneal dialysis), recruited from Chang Gung Memorial Hospital in November 2020. Patients were stratified into two groups by their blood aluminum levels, as normal (<2 µg/dL, n = 1150) or abnormal (≥2 µg/dL, n = 25). Results. The patients aged 60.4 ± 13.2 years and were dialyzed for 8.6 ± 8.1 years. The average blood aluminum level was 1.0 ± 0.4 µg/dL. Patients with abnormal blood aluminum levels received more sevelamer than patients with normal blood aluminum level (p = 0.014). Patients with abnormal blood aluminum levels had higher platelet count (p = 0.001), triglyceride (p < 0.001) and total iron binding capacity (p = 0.003) than patients with normal blood aluminum levels. Moreover, the cardiothoracic ratio was higher in patients with abnormal blood aluminum levels than patients with normal blood aluminum levels (p = 0.003). Conclusions. The prevalence of abnormal blood aluminum levels was low at 2.2%. Nevertheless, the linking of cardiothoracic ratio of more than 0.5 as well as elevated blood platelet count and triglyceride level with blood aluminum levels are interesting, and warranted more researches in this area.
format Online
Article
Text
id pubmed-8997989
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89979892022-04-12 Blood Aluminum Levels in Patients with Hemodialysis and Peritoneal Dialysis Chuang, Po-Hsun Tsai, Kai-Fan Wang, I-Kuan Huang, Ya-Ching Huang, Lan-Mei Liu, Shou-Hsuan Weng, Cheng-Hao Huang, Wen-Hung Hsu, Ching-Wei Lee, Wen-Chin Yen, Tzung-Hai Int J Environ Res Public Health Article Background. This retrospective observational study attempted to examine the prevalence of abnormal blood aluminum levels in dialysis patients, and to explore the association of pathogenic factors, such as demographic, clinical, laboratory as well as the use of phosphate binding drugs, drugs for secondary hyperparathyroidism and erythropoiesis-stimulating drugs with the blood aluminum levels. Methods. The study included 1175 patients (874 hemodialysis and 301 peritoneal dialysis), recruited from Chang Gung Memorial Hospital in November 2020. Patients were stratified into two groups by their blood aluminum levels, as normal (<2 µg/dL, n = 1150) or abnormal (≥2 µg/dL, n = 25). Results. The patients aged 60.4 ± 13.2 years and were dialyzed for 8.6 ± 8.1 years. The average blood aluminum level was 1.0 ± 0.4 µg/dL. Patients with abnormal blood aluminum levels received more sevelamer than patients with normal blood aluminum level (p = 0.014). Patients with abnormal blood aluminum levels had higher platelet count (p = 0.001), triglyceride (p < 0.001) and total iron binding capacity (p = 0.003) than patients with normal blood aluminum levels. Moreover, the cardiothoracic ratio was higher in patients with abnormal blood aluminum levels than patients with normal blood aluminum levels (p = 0.003). Conclusions. The prevalence of abnormal blood aluminum levels was low at 2.2%. Nevertheless, the linking of cardiothoracic ratio of more than 0.5 as well as elevated blood platelet count and triglyceride level with blood aluminum levels are interesting, and warranted more researches in this area. MDPI 2022-03-24 /pmc/articles/PMC8997989/ /pubmed/35409569 http://dx.doi.org/10.3390/ijerph19073885 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chuang, Po-Hsun
Tsai, Kai-Fan
Wang, I-Kuan
Huang, Ya-Ching
Huang, Lan-Mei
Liu, Shou-Hsuan
Weng, Cheng-Hao
Huang, Wen-Hung
Hsu, Ching-Wei
Lee, Wen-Chin
Yen, Tzung-Hai
Blood Aluminum Levels in Patients with Hemodialysis and Peritoneal Dialysis
title Blood Aluminum Levels in Patients with Hemodialysis and Peritoneal Dialysis
title_full Blood Aluminum Levels in Patients with Hemodialysis and Peritoneal Dialysis
title_fullStr Blood Aluminum Levels in Patients with Hemodialysis and Peritoneal Dialysis
title_full_unstemmed Blood Aluminum Levels in Patients with Hemodialysis and Peritoneal Dialysis
title_short Blood Aluminum Levels in Patients with Hemodialysis and Peritoneal Dialysis
title_sort blood aluminum levels in patients with hemodialysis and peritoneal dialysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997989/
https://www.ncbi.nlm.nih.gov/pubmed/35409569
http://dx.doi.org/10.3390/ijerph19073885
work_keys_str_mv AT chuangpohsun bloodaluminumlevelsinpatientswithhemodialysisandperitonealdialysis
AT tsaikaifan bloodaluminumlevelsinpatientswithhemodialysisandperitonealdialysis
AT wangikuan bloodaluminumlevelsinpatientswithhemodialysisandperitonealdialysis
AT huangyaching bloodaluminumlevelsinpatientswithhemodialysisandperitonealdialysis
AT huanglanmei bloodaluminumlevelsinpatientswithhemodialysisandperitonealdialysis
AT liushouhsuan bloodaluminumlevelsinpatientswithhemodialysisandperitonealdialysis
AT wengchenghao bloodaluminumlevelsinpatientswithhemodialysisandperitonealdialysis
AT huangwenhung bloodaluminumlevelsinpatientswithhemodialysisandperitonealdialysis
AT hsuchingwei bloodaluminumlevelsinpatientswithhemodialysisandperitonealdialysis
AT leewenchin bloodaluminumlevelsinpatientswithhemodialysisandperitonealdialysis
AT yentzunghai bloodaluminumlevelsinpatientswithhemodialysisandperitonealdialysis